Drugs and Pharmaceuticals Industry News from Send2Press Newswire
News Index for Sunday, March 01, 2015
Click any story headline below to read full press release.
= Video News Release (VNR)
= Video News Release (VNR)
Wed, 11 Feb 2015, 13:39:11 EST
NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) -- Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs' steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.
Wed, 15 Oct 2014, 14:29:43 EST
PORTLAND, Ore., Oct. 15, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, will be exhibiting at the American Academy of Ophthalmology (Booth #4550) in Chicago, Ill., on October 18 - 21.
Tue, 14 Oct 2014, 09:00:42 EST
PLYMOUTH, Minn., Oct. 14, 2014 (SEND2PRESS NEWSWIRE) -- SilkTears, LLC, a privately held, research-based and product-driven biotechnology company, announced today that advances in protein-based excipient technology may allow for the development of artificial tear products that will more closely represent certain characteristics of the natural makeup of the tear film, and may help the significant population of patients suffering from dry eye syndrome.
National Law Journal Names Weitz and Luxenberg to 'Elite Trial Lawyers' List, Reveals 2 Keys to Firm's $9-Billion Actos Verdict
Wed, 01 Oct 2014, 13:50:01 EST
NEW YORK, N.Y., Oct. 1, 2014 (SEND2PRESS NEWSWIRE) -- Two keys that earlier this year led to a $9-billion courtroom victory by Weitz and Luxenberg, P.C., against the maker of the diabetes drug Actos, were revealed Monday when National Law Journal named the New York City-based personal injury firm to its debut list of 'America's Elite Trial Lawyers.'
Lakewood College announces program to allow students to graduate from the Pharmacy Technician Certificate Program debt-free
Tue, 01 Jul 2014, 09:00:09 EST
CLEVELAND, Ohio, July 1, 2014 (SEND2PRESS NEWSWIRE) -- Lakewood College is pleased to announce a new payment plan option that will allow students to graduate from the Pharmacy Technician Certificate Program without going thousands of dollars into debt.
Paragon BioTeck announces FDA Approved Phenylephrine Hydrochloride Ophthalmic Solution Readily Available
Wed, 04 Jun 2014, 11:31:56 EST
PORTLAND, Ore., June 4, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held U.S. biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, announces its FDA approved Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil, is readily available through Bausch + Lomb or your primary wholesaler.
Mon, 19 May 2014, 13:14:01 EST
COOPER CITY, Fla., May 19, 2014 (SEND2PRESS NEWSWIRE) -- Forever Young MedSpa announces that it was recently granted a registered trademark for PRP Gold(R), its exclusive platelet rich plasma (PRP) for treating skin conditions. 'PRP treatments have become very popular over the past few years,' Brian Sidella, president and founder Forever Young MedSpa, says.
Wed, 09 Apr 2014, 18:16:50 EST
NEW YORK CITY, N.Y., April 9, 2014 (SEND2PRESS NEWSWIRE) -- A Louisiana jury has awarded $9 billion to a New York man who developed bladder cancer after taking Actos, Weitz and Luxenberg announced today. The verdict, issued Monday night, orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.
Wed, 09 Apr 2014, 06:00:29 EST
PORTLAND, Ore., April 9, 2014 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held biopharmaceutical company specializing in the development of ophthalmic pharmaceuticals and therapies, received FDA approval of Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5 percent and 10 percent, to dilate the pupil on March 21, 2013.
Fri, 08 Nov 2013, 17:19:12 EST
PORTLAND, Ore., Nov. 8, 2013 (SEND2PRESS NEWSWIRE) -- Leading biopharmaceutical company Paragon BioTeck, Inc. announced today that it plans to launch its new line of products, known as Ilast(R), at the Annual American Academy of Ophthalmology meeting in New Orleans. Paragon signed an exclusive distribution agreement with Horus Pharma to supply Ilast(R) ocular care products in the U.S. last month, and the company is excited to release these products to ophthalmology professionals.
Wed, 06 Nov 2013, 17:26:07 EST
CHICAGO, Ill., Nov. 6, 2013 (SEND2PRESS NEWSWIRE) -- Natural supplement company Nutronics Labs released a statement today encouraging deer antler spray consumers to do thorough product research before buying health supplements online. Nutronics Labs is the leading manufacturer of deer antler spray and boasts the world's strongest supplements available - but as the popularity of their products continues to grow, they have seen hundreds of imitation products flood the market recently.
Wed, 09 Oct 2013, 12:59:11 EST
PORTLAND, Ore., Oct. 9, 2013 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. today announced that it has signed a distribution agreement with Horus Pharma for rights to supply the Ilast(R) range of its medical-grade ocular hygiene and lid care products within the United States; it begins on an exclusive basis this month.
Wed, 04 Sep 2013, 05:00:05 EST
DURHAM, N.C., Sept. 4, 2013 (SEND2PRESS NEWSWIRE) -- HeartIT, the global leader that pioneered the first FDA approved zero-footprint medical imaging workstation, announced today that it has received a $2.5M grant from the NIH in order to develop the 'Cloud Based Corelab of the Future.'
Fri, 19 Apr 2013, 19:04:12 EST
MADISON, N.J. and TIGARD, Ore., April 19, 2013 (SEND2PRESS NEWSWIRE) -- Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.
CMI's Paul Gondek and Alisa Hamilton to Co-Present with Deanna Schwarz of Pfizer at 2013 PRMG Annual National Conference
Thu, 07 Mar 2013, 16:36:23 EST
ATLANTA, Ga., March 7, 2013 (SEND2PRESS NEWSWIRE) -- CMI and Pfizer will co-present 'Engaging Stakeholders with A Story - 3 Tips to Improve Research Reporting' at the PMRG's upcoming National Annual Conference March 10-12 in National Harbor, Md.
Thu, 28 Feb 2013, 17:49:29 EST
DOVER, Pa., Feb. 28, 2013 (SEND2PRESS NEWSWIRE) -- RXCut(R) Plus announced this week a new website that is designed to help people get the best prescription price available. The Centers for Medicare and Medicaid (CMS) report that in 2014, prescription drug spending is expected to grow at a rate of 10.7 percent.
Mon, 25 Feb 2013, 12:59:28 EST
MILLVILLE, N.J., Feb. 25, 2013 (SEND2PRESS NEWSWIRE) -- Laboratory Supply Distributors Corp., a provider of diverse products for the chromatography, biotechnology, pharmaceutical and environmental industries, this week announced the launch of its 2013 catalog. It showcases many new products for the life science and biotechnology markets.
Thu, 07 Feb 2013, 15:05:14 EST
ATLANTA, Ga., Feb. 7, 2013 (SEND2PRESS NEWSWIRE) -- CMI, a leader in marketing research services and insight, announced today that Beth Thompson has joined as Vice President, Qualitative Research. Thompson brings a 20-year track record of successfully conducting highly complex domestic and global marketing research.
Thu, 18 Oct 2012, 12:52:47 EST
BRIDGEPORT, Conn., Oct. 18, 2012 (SEND2PRESS NEWSWIRE) -- October is the month the kids begin to scratch, says George Coleman, founder and president of Connecticut's Dermedics Laboratories. That's because the start of a new school year has children literally putting their heads together - and that's how head lice infestations get started.
Fri, 28 Sep 2012, 04:55:06 EST
ATLANTA, Ga., Sept. 28, 2012 (SEND2PRESS NEWSWIRE) -- Paul Gondek has joined CMI to expand the company's Healthcare Solutions practice to support healthcare, pharmaceutical, and medical device companies. As vice president client solutions and healthcare lead, Gondek will further enhance an experienced pharmaceutical team, using advanced analytics and immersive techniques to provide strategic insights that brand teams can use.
From Hangovers to Head Lice: What Do Head Lice and Hangovers Have in Common? CT-based Healthcare Entrepreneur George Coleman
Mon, 02 Jul 2012, 16:31:12 EST
BRIDGEPORT, Conn., July 2, 2012 (SEND2PRESS NEWSWIRE) -- In the early 1980's George Coleman, head of Dermedics Laboratories in Bridgeport, Conn., teamed up with the former Keneric Industries to reformulate and market an over-the-counter pharmaceutical product designed to treat the symptoms of hangovers. The product, Dr. Seltzer's Hangover Helper, went on to become the best-selling hangover remedy in the U.S. It was eventually sold to a well-known manufacturer and, after almost 20 years on the market, was discontinued when that manufacturer was sold.
Thu, 08 Mar 2012, 13:47:39 EST
ATLANTA, Ga., March 8, 2012 (SEND2PRESS NEWSWIRE) -- CMI's Mike Mabey, vice president, client solutions, and Jarod Ricci, senior manager, market analytics, Pfizer Specialty, will present 'Using Information-Seeking Behavior to Drive Segment-Specific Communication Strategies' at the 2012 PMRG (Pharmaceutical Marketing Research Group) Annual National Conference.
Tue, 21 Feb 2012, 06:58:22 EST
PHILADELPHIA, Pa., Feb. 21, 2012 (SEND2PRESS NEWSWIRE) -- E'shee Clinical Esthetic announced this week a new addition to its product line of skin serums - Elixir of Life KI Therapy Serum - designed to deliver ultimate skin rejuvenation.
Tue, 14 Feb 2012, 07:59:03 EST
NEW WINDSOR, N.Y., Feb. 14, 2012 (SEND2PRESS NEWSWIRE) -- Mary Davidian, M.D., of Highland Ophthalmology Associates, a leading eye surgeon in The Hudson Valley, announces offering her patients a unique corneal wound repair and healing device called ProKera(R). Today, ProKera(R) is the only medical device that can provide wound healing to patients afflicted with a damaged cornea, the outer transparent surface of the eye.
Wed, 08 Feb 2012, 15:54:08 EST
AUSTIN, Texas, Feb. 8, 2012 (SEND2PRESS NEWSWIRE) -- Bio-Medical Services has received USDA approval and is now offering allergy drop immunotherapy as an alternative method for administering allergy treatment for pet allergy patients. An in-house pilot study is now underway, and preliminary findings are expected in the Fall of 2012.
Wed, 01 Feb 2012, 06:57:11 EST
HIGHLAND PARK, N.J., Feb. 1, 2012 (SEND2PRESS NEWSWIRE) -- 2012 marks an important milestone for Belvidere Pharmacy. It opened new doors in its new hometown of Highland Park. When owner and President Shara Rudner, R.Ph. took the reins of the business in 1996, it was a typical retail pharmacy stocked with everything from school to surgical supplies. But from the beginning, Belvidere's staff handled requests for compounded, or custom-made, medications from veterinarians, physicians and specialists.
Reaction Biology Corporation Unveils Largest Kinase Profiling Data Set in Nature Biotechnology Publication
Mon, 31 Oct 2011, 03:57:54 EST
MALVERN, Pa., Oct. 31, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC') today announced the publication in Nature Biotechnology, of the largest kinase profiling data set in the public domain, disclosing previously unknown kinase inhibition relationships. The data set was compiled from over 100,000 independent activity assays performed with RBC's proprietary HotSpot(SM) technology.
Mon, 24 Oct 2011, 14:25:48 EST
MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ('RBC'), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC's initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
Soy Labs and Missouri Plant Science Center in Governor's Spotlight for Innovative and Economic Development
Tue, 20 Sep 2011, 06:59:33 EST
MEXICO, Mo., Sept. 20, 2011 (SEND2PRESS NEWSWIRE) -- Missouri Gov. Jay Nixon, whose job-creation strategy has focused on investing in science, technology and innovation, and encouraging and incentivizing entrepreneurship, selected Soy Labs and the Missouri Plant Science Center on Friday, as the site to discuss the importance of the Missouri House passing the Missouri Science and Innovation Reinvestment Act (MOSIRA) as part of the Made in Missouri Jobs Package.
Wed, 03 Aug 2011, 08:59:36 EST
PHILADELPHIA, Pa. (SEND2PRESS NEWSWIRE) -- E'shee Clinical Esthetic introduces the next step in anti-aging skin care - White Truffle Radiance Cream - an amazingly powerful skin anti-oxidant. This supremely elegant formula combines the finest bioengineering technologies, and offers skin the most effective anti-oxidant protection and luxurious brightening action ever experienced in skincare formulation
Millennium Administrators, Inc. Has Been Selected by The City of Scranton, Pennsylvania to Provide Benefit Administration for Active Fire and Police
Tue, 12 Jul 2011, 18:45:03 EST
SCHWENKSVILLE, Pa. (SEND2PRESS NEWSWIRE) -- Millennium Administrators, Inc., a benefits administrator, has signed a contract with the City of Scranton to provide benefit administration services for over 500 city employees. Millennium is providing administrative oversight for the city benefit program, including cost containment initiatives, claim audits and administrative services to enhance cost saving initiatives at the City of Scranton.
Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation from the U.S. FDA
Mon, 28 Feb 2011, 18:53:36 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that the U.S. FDA has granted Phase 3 status for Company's lead anti-cancer agent, Rexin-G, the first, and so far only, targeted gene delivery system developed to seek-out and destroy metastatic cancer.
Business & Decision and New Strategies Partner in Order to Bring Industry Leading ERP Solutions to the Pharmaceutical Industry
Mon, 03 Jan 2011, 17:30:56 EST
PHOENIX, Ariz. (SEND2PRESS NEWSWIRE) -- As a part of Business & Decision's ongoing focus in the Life Science market, we are delighted to announce a partnership with New Strategies, the creators of 'AX for Pharma' an industry leading Enterprise Resource Planning solution for the Pharmaceutical industry. This solution, which is based on Microsoft Dynamics AX, has been designed to address the primary business process needs of a Life Science / Pharmaceutical organization.
Thu, 09 Dec 2010, 12:00:10 EST
SOMERSET, N.J. (SEND2PRESS NEWSWIRE) -- From the blogosphere to mainstream media, there's been a recent-and disturbing-buzz on a connection between hormone replacement therapy and a higher risk for advanced-stage breast cancer in post-menopausal women. The recent media focus stems from a study published in the October 2010 issue of the Journal of the American Medical Association (JAMA). Practitioners from Belvidere Pharmacy and Balancing Health, both experts in women's health, examine the issue.
Wed, 17 Nov 2010, 18:09:23 EST
NORTH PLAINFIELD, N.J. (SEND2PRESS NEWSWIRE) -- For the second time in its history, Belvidere Pharmacy of North Plainfield has secured the coveted Pharmacy Compounding Accreditation Board's (PCAB) Seal of Accreditation. Registered in New York, New Jersey and Connecticut, Belvidere was the first and is still the only accredited PCAB pharmacy in the New York metro area. It has held this distinction since 2007.
Mon, 08 Nov 2010, 11:47:57 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, announced today the receipt of additional financial support for the company's lead oncology product, Rexin-G, from the U.S. Departments of Treasury, Health and Human Services (HHS), and the National Institutes of Health (NIH) in the form of a prestigious competitive grant.
Tue, 12 Oct 2010, 15:28:46 EST
ATLANTA, Ga. (SEND2PRESS NEWSWIRE) -- CMI, a full-service marketing research company, has been chosen for the second consecutive year to present a session at The Fourth Annual Meeting of the PMRG Institute in Boston, MA on Oct. 24-26, 2010. The theme for this year's conference is 'Navigating Healthcare's Shifting Currents: Essential Techniques for the Healthcare Marketing Researcher.'
To Reach, Perchance to Kill the Cancer: A Soliloquy from Epeius Nanotechnologies Opposes that 'Sea of Troubles'
Tue, 07 Sep 2010, 20:46:15 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the emerging field of targeted genetic medicine, reports the publication of a landmark paper in clinical oncology. Following up on its advanced U.S. Phase I/II clinical trials of Rexin-G in chemo-resistant metastatic pancreatic cancer (Molecular Therapy, 2010, 18: 435-441), which gained both Orphan Drug and FDA Fast Track Status, this new paper documents the molecular mechanisms-of-action of Rexin-G.
Wed, 11 Aug 2010, 15:54:06 EST
MALVERN, Pa. (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpot drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more.
Small, Smart, Stealth Nanoparticles Seek-and-Destroy Metastatic Cancers, as Epeius Biotechnologies Advances its Intellectual Property Estate with Additional U.S. Patents
Tue, 06 Jul 2010, 16:42:17 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for another crucial patent covering its leading tumor-targeted gene delivery platform. The issuance of this high-value patent protection for targeting metastatic disease follows on the heels of two major patent issuances.
Fri, 18 Jun 2010, 17:14:51 EST
NEW CASTLE, Pa. (SEND2PRESS NEWSWIRE) -- The Signature Hill Substance Abuse Network, a program dedicated to linking the legal system and treatment of substance abuse through the use of Vivitrol(R) injections has garnered acclaim in media outlets. Articles lauding the program have recently cited the Network's approach to eliminating the consumer demand for drugs and alcohol by eliminating cravings with the use of Vivitrol.
Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
Tue, 01 Jun 2010, 12:29:15 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the results of the clinical trial entitled 'Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma' at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.
Tumor-targeted Rexin-G Prolongs Survival in Gemcitabine-resistant Metastatic Pancreas Cancer in Advanced Phase I and II Studies (ASCO 2010)
Mon, 24 May 2010, 18:44:14 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the results of the clinical study entitled 'Phase I and II Studies of Intravenous Rexin-G as Monotherapy for Gemcitabine-resistant Metastatic Pancreas Cancer' at the ASCO Annual Meeting on June 6, 2010. The presentation will be discussed by Dr. Howard W. Bruckner, Bruckner Oncology, New York, NY.
Tumor-Targeted Nanoparticle-based Gene Delivery Provides Evidence of Therapeutic Vaccination in Patients with Metastatic Cancer (ASCO 2010)
Mon, 24 May 2010, 13:06:41 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announces the clinical results of the study entitled 'A Phase I/II Study of Intravenous Rexin-G and Reximmune-C for Cancer Immunotherapy: The GeneVieve Protocol' at the ASCO Annual Meeting on June 6, 2010. The presentation will be made by Dr. Jorge G. Ignacio, Chairman of the Cancer Institute and Bioethics Committee-Philippine General Hospital, and Principal Investigator of the study.
Epeius Biotechnologies Reports Major Clinical Advances: Noteworthy Clinical Case Studies in Cancer Gene Therapy
Tue, 04 May 2010, 12:06:12 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in the field of targeted genetic medicine, reports the publication of three major publications in the field. The first article entitled 'Rexin-G, A Targeted Genetic Medicine for Metastatic Cancer' (Expert Opinion on Biological Therapy, May, 2010) documents the development of Rexin-G: a tumor-targeted retrovector bearing a cytocidal cyclin G1 construct; the first targeted gene therapy vector to gain FDA Fast Track designation and Orphan Drug priorities for multiple cancer indications in the USA.
Wed, 21 Apr 2010, 12:09:32 EST
GREENSBORO, N.C. (SEND2PRESS NEWSWIRE) -- Millions of dogs suffer from canine arthritis and their owners often have no idea their beloved pets are in such pain. A new initiative spearheaded by Novartis Animal Health US, Inc. and Hill's Pet Nutrition will combat that disconnect with a goal of screening one million dogs for canine arthritis. The two companies teamed up to launch the 'Million Dog Search,' a nationwide awareness campaign that will also raise thousands of dollars for animal charities, including Paws of Life.
Eularis Updates Reports That Help Pharmaceutical Companies Do More for Real Growth Than Simply Downsizing
Mon, 05 Apr 2010, 13:58:19 EST
LONDON, U.K. (SEND2PRESS NEWSWIRE) -- The pharmaceutical industry is facing unprecedented challenges on many fronts - a slew of patient expiries, a lack of blockbusters in the pipeline to replace the patent expiries, decreasing growth in many major markets, generic competition, constantly changing regulatory and competitive environment rendering old tools for analysis obsolete, increased pressure on CEOs to deliver shareholder growth resulting in budget cuts, downsizing, and less than optimal results.
Tue, 16 Mar 2010, 06:58:47 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, received a notice of allowance from the USPTO for a crucial patent covering its leading tumor-targeted vaccine technology for cancer immunotherapy. The issuance of this valuable patent protection for tumor targeted immunotherapy follows on the heels of two international patents covering targeted gene medicine in the U.S. and Europe and places Epeius at the forefront of these emerging fields of clinical medicine.
Tue, 09 Mar 2010, 13:51:05 EST
EUGENE, Ore. (SEND2PRESS NEWSWIRE) -- Noble Vision Group, LLC, a research and development organization today announced reports of favorable results for the topical dye formulation, Fluramene(TM), among leading eye care professionals. Fluramene, the proprietary Fluorescein Sodium and Lissamine Green dye combination is a sterile solution packaged in a 15mL bottle with a control tip dropper. The benefits of both dyes have been studied comprehensively and are well reported as diagnostic tools used independent of each other.
Thu, 18 Feb 2010, 20:53:21 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century.
Scientists Rediscover Gene Target for Cancer Therapy - Rexin-G Receives High-tech Validation as Strategic Anti-cancer Agent
Tue, 15 Dec 2009, 12:10:59 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, gained international validation of the cutting-edge science behind its lead oncology product, Rexin-G, when scientists around the world rediscovered the Cyclin G1 gene to be a major locus of cancer pathogenesis and disease progression, and thus a prime target for anti-cancer therapies.
Tue, 20 Oct 2009, 13:17:36 EST
SAN FRANCISCO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com), an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco.
Advanced U.S. Clinical Trial Confirms Single-Agent Efficacy of Rexin-G in Metastatic Pancreas Cancer: All Endpoints Achieved
Wed, 14 Oct 2009, 05:59:50 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer. Following Phase I studies at the Mayo Clinic, which affirmed the general safety of Rexin-G, advanced U.S. Phase I/II studies were undertaken, which included a Phase II efficacy component and examined progressive dose escalations of Rexin-G.
Clinical Remissions in Three Otherwise Intractable Cancers Signal the Progress of Targeted Genetic Medicine
Mon, 12 Oct 2009, 13:49:28 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has once again accomplished what standard cancer treatments and even much-touted biologics have failed to do: that is, to bring forth the benefits of remission in otherwise intractable metastatic cancers.
Tue, 15 Sep 2009, 07:59:29 EST
NEW YORK CITY, N.Y. (SEND2PRESS NEWSWIRE) -- As Mark Whitacre, COO of Cypress Systems, Inc., prepares to walk the red carpet on September 15 during the premiere of 'The Informant,' he has something to say: he is NOT the same man who blew the whistle on his employer in the early 1990's, putting him in the spotlight of one of the largest price-fixing schemes in corporate history and ultimately landing him in federal prison for over eight years.
Pharmaceutical eMarketing using Social Media: How to Use It Effectively, Meet the Challenges (Regulatory and Others) and Measure Results in Dollar Terms
Tue, 08 Sep 2009, 13:22:43 EST
NEW YORK, N.Y. and LONDON, U.K. (SEND2PRESS NEWSWIRE) -- Eularis is announcing the release of its report 'How To Harness The Power Of Social Media In Pharmaceutical eMarketing.' This report puts to rest the issues around 'can't,' and shows Pharmaceutical marketers how they can utilize social media networks effectively to meet their marketing objectives.
Potential Silver Bullet for Swine Flu and Most Common Infections Using Green Technology Patented in U.S. and Mexico
Wed, 24 Jun 2009, 13:48:07 EST
FORT LAUDERDALE, Fla. (SEND2PRESS NEWSWIRE) -- Argentech, Inc. today announced that it reached agreement with Invision International Health Solutions, Inc., to purchase the rights to Opti-Silver, a patented antibacterial and antiviral technology that utilizes ionic silver in a unique complex for optimal delivery in the human body. The complex was granted broad patent protection in the U.S. and, recently, in Mexico as well. It also has patent protection overseas.
Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival
Mon, 22 Jun 2009, 12:45:51 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article documents the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body.
Epeius Biotechnologies' Rexin-G Receives FDA Fast Track Designation for the Treatment of Pancreatic Cancer
Wed, 17 Jun 2009, 06:00:17 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for use as a second-line treatment for advanced or metastatic pancreatic cancer. The FDA Fast Track program, like Priority Review and Accelerated Approval, was implemented to facilitate the development and expedite the review of potentially important new drugs.
Tue, 09 Jun 2009, 07:59:24 EST
SAN MARINO, Calif. (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies' Rexin-G is the world's smallest hero. Imagine if you will, a tiny particle that can travel freely within the human body seeking out cancerous tissues and metastatic tumors that have spread far and wide. Imagine an entire army of these tiny nano-particles seeking out and accumulating to high concentrations within the flagrant, otherwise intractable tumors with one goal in mind: to destroy the metastatic cancers from the inside.
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
Mon, 18 May 2009, 12:45:19 EST
SAN MARINO, Calif., May 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies today announced the results of two related studies using Rexin-G®, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S.
Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
Thu, 12 Feb 2009, 15:58:45 EST
SAN MARINO, Calif., Feb. 12 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is designed to seek-out and destroy metastatic cancers that are resistant to chemotherapy and which have spread throughout the body.
Rexin-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer
Mon, 19 Jan 2009, 20:32:23 EST
SAN MARINO, Calif., Jan. 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced the results of a U.S. Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic pancreatic cancer (ASCO GI Symposium, #249; Sant P Chawla, P.I., January 2009). Rexin-G was well tolerated and there was no dose-limiting toxicity. At Dose Level I, three patients achieved stable disease with no tumor progression; and at Dose Level II, one patient had a 37 percent decrease in tumor size and five patients exhibited disease stabilization with no tumor progression.
Silver Safety Pyramid Provides Guidelines for Safe Usage of Any Ionic Silver or Colloidal Silver Supplement
Thu, 08 Jan 2009, 07:59:47 EST
FORT LAUDERDALE, Fla., Jan. 8 (SEND2PRESS NEWSWIRE) -- The Silver Safety Committee today announced its creation of the Silver Safety Pyramid, which is designed to enable anyone to easily determine safe usage levels of any dietary supplement containing silver, typically referred to as ionic silver or colloidal silver.
Epeius Biotech Awarded Patents in Europe for Targeted Genetic Anti-Cancer Medicine: Company Expands Impressive Intellectual Property Estate
Tue, 16 Dec 2008, 11:36:13 EST
SAN MARINO, Calif., Dec. 16 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, a leader in tumor-targeted gene delivery systems, has received two additional European patents for the platform targeting technologies and molecular designs that enable precision gene delivery to primary cancers and metastatic lesions that have spread throughout the body. With profound demonstrations of clinical benefit and single-agent-efficacy, as well as overall safety, Epeius Biotech continues to lead the field of clinical gene medicine with the advent of pathotropic targeting.
Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma
Thu, 20 Nov 2008, 19:28:29 EST
SAN MARINO, Calif., Nov. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of Phase I/II and II studies of Rexin-G in chemotherapy-resistant metastatic soft tissue sarcoma and osteosarcoma, as presented by Dr. Sant P. Chawla, principal investigator, at the CTOS 14th annual meetings held in London UK on November 13-15, 2008. Patients received repeated infusions of Rexin-G i.v. over a period up to 9 months.
Mon, 17 Nov 2008, 09:48:13 EST
NEW YORK, LONDON, TOKYO, Nov. 17 (SEND2PRESS NEWSWIRE) -- In today's environment, Pharmaceutical companies find themselves in a bind. Drug launches used to be able to achieve high sales and profits - until recently. Every Pharma company today is hoping to achieve their own immediate winners, the drugs that are successful right from the start and provide years of business-sustaining profit. However, recent studies have shown that seven out of ten drugs launched in the last five years have failed to repay their R&D investment.
Rexin-G Returns to The Big Apple: Clinical Trials for Pancreatic Cancer and Breast Cancer Open in Manhattan
Wed, 29 Oct 2008, 15:11:24 EST
SAN MARINO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of clinical trials using intravenous Rexin-G for pancreatic cancer and breast cancer in Manhattan, New York. Rexin-G is the world's first tumor-targeted genetic medicine that is designed to seek out and destroy both primary tumors and metastatic cancers that have spread throughout the body.
Wed, 29 Oct 2008, 11:50:00 EST
FRESNO, Calif., Oct. 29 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc, a Fresno CA based biotechnology company, emphasizes that the SELECT TRIAL results - that were announced yesterday - used a form of selenium known as selenomethionine. The SELECT TRIAL found no effects of either selenomethionine or vitamin E on the incidence of prostate cancer. See Related Website at cypsystems.com.
Targeting Metastatic Cancer from the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
Mon, 06 Oct 2008, 12:14:50 EST
SAN MARINO, Calif., Oct. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled 'Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ,' was published in the October issue of the International Journal of Oncology.
Tue, 16 Sep 2008, 15:07:49 EST
NEW YORK, N.Y. and LONDON, U.K., Sept. 16 (SEND2PRESS NEWSWIRE) -- Eularis today announced the release of a first-ever study on the ROI of named patient programmes (NPP), also known as compassionate use programs. The paper, 'Implementing a pre-launch named patient programme - evidence of increased market share,' provides pharmaceutical companies with insight and mathematical justification into the cash market share and revenue impact of pre-launch NPPs on brands, while outlining the benefits and challenges that they create.
Epeius Biotechnologies' Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
Mon, 15 Sep 2008, 11:06:58 EST
SAN MARINO, Calif., Sept. 15 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G, its lead product in development for metastatic cancer, has been highlighted in a recent NEWS article published by the Journal of the National Cancer Institute (JNCI, Sept. 9, 2008). The article, authored by Vickie Brower, describes recent advances and new approaches in genetic medicine that may succeed where small molecules and proteins have failed.
Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma
Tue, 08 Jul 2008, 14:42:48 EST
SAN MARINO, Calif., July 8 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Rexin-G has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of osteosarcoma. Based on several criteria, including the rarity, seriousness, and current lack of effective therapies for metastatic osteosarcoma, as well as the scientific and medicinal merit of Rexin-G, the granting of Orphan Drug Status by the FDA validates the unique clinical development strategy.
Thu, 29 May 2008, 13:19:21 EST
SAN MARINO, Calif., May 29 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic bone and soft tissue sarcoma (J Clin Oncol 26: 14509, 2008). Rexin-G is the first and so far only targeted gene therapy vector that has been tested in the clinic (Nature Reviews/Genetics 2007).
Wed, 28 May 2008, 01:05:25 EST
RICHMOND, Texas (SEND2PRESS NEWSWIRE) -- CYNACON / OCuSOFT(R) (OCuSOFT(R), Inc.), a company specializing in ophthalmic research, development and supply to ophthalmologists and optometrists, is pleased to announce that as a convenience to all patients, OCuSOFT(R) Lid Scrub(TM) Plus is now available in CVS pharmacies, nationwide.
Tue, 27 May 2008, 11:40:00 EST
SAN MARINO, Calif., May 27 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today that the results of a Phase I Feasibility Study of sequential targeted gene delivery-using Rexin-G followed by Reximmune-C-for cancer vaccination will be presented at the ASCO meetings in Chicago on June 1, 2008 (J Clin Oncol 26:3077, 2008). Rexin-G and Reximmune-C are pathotropic (disease-seeking) nanoparticles bearing a cytocidal cyclin G1 gene and a granulocyte-macrophage colony stimulating factor (GM-CSF) gene, respectively.
TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
Thu, 22 May 2008, 12:46:02 EST
SAN MARINO, Calif., May 22 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the promising results of an on-going United States-based Phase I/II study of Rexin-G for metastatic breast cancer that is refractory to conventional chemotherapy (J Clin Oncol 26:14509, 2008). This clinical trial employed intra-patient dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks, with doses ranging from 2 x 10e11 cfu to 6 x 10e11 cfu per week.
ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer
Mon, 19 May 2008, 07:10:36 EST
SAN MARINO, Calif., May 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the results of an on-going Phase I/II study of Rexin-G for metastatic pancreatic cancer (Chawla et al., ASCO meeting, 2008). Continuing on with the planned dose-escalations of Rexin-G which began in 2005 using lower doses of Rexin-G in a Phase I safety study (Molecular Therapy, 2008), the current Phase I/II study employed higher dose-escalations of Rexin-G given i.v. two to three times a week for 4 weeks.
Mon, 12 May 2008, 01:25:00 EST
TOKYO and LONDON, U.K., May 12 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the New York and London-based pharmaceutical analytics company Eularis, will be delivering a presentation on how to tell if you are making the wrong marketing decision. The Pharmaceutical Marketing Excellence conference takes place in Tokyo, Japan.
Mon, 21 Apr 2008, 10:49:23 EST
NEW YORK, N.Y. and LONDON, U.K., April 21 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on Making the Right Research Decision for ROI - The Link Between Research and Decisions on Bottom Line Return, at 3rd Annual Pharmaceutical Market Research Summit.
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Mon, 21 Apr 2008, 08:30:26 EST
SAN MARINO, Calif., April 21 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer.
Tue, 15 Apr 2008, 01:03:26 EST
FRESNO, Calif., April 15 (SEND2PRESS NEWSWIRE) -- Chairman and CEO, Paul Willis stated, 'Just like his previous career at a large agribusiness company, Dr. Mark E. Whitacre has risen fast at Cypress Systems, Inc, last month being named the company's chief operating officer and president of operations.' Now Cypress and Whitacre are focusing their energy on an aggressive cancer prevention campaign in order to get Americans-and people around the world-to consume a special type of selenium known as SelenoExcell(R).
Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him
Tue, 25 Mar 2008, 02:00:11 EST
FRESNO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Cypress Systems, Inc., a Fresno CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new east coast office.
Tue, 25 Mar 2008, 01:05:29 EST
SAN MARINO, Calif., March 25 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the issue of U.S. Patent No. 7,347,998 for Targeted Gene Delivery in vivo. This patent provides additional intellectual property protection for the platform of highly advanced biotechnologies embodied in the company's leading anti-cancer agent, Rexin-G.
Wed, 12 Mar 2008, 13:16:18 EST
NEW YORK, N.Y. and LONDON, U.K., March 12 (SEND2PRESS NEWSWIRE) -- Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, 'Ensuring Profitable Patient Adherence Programs.'
MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London
Mon, 10 Mar 2008, 12:50:35 EST
NEW YORK, N.Y. and LONDON, U.K., March 10 (SEND2PRESS NEWSWIRE) -- Dr. Andree Bates, president of the pharmaceutical analytics company Eularis, will be delivering a presentation on meeting the challenges of measuring ROI within the changing dynamics of the pharma industry.
Thu, 06 Mar 2008, 12:32:05 EST
SALT LAKE CITY, Utah, March 6 (SEND2PRESS NEWSWIRE) -- The same diet that's helping you lose weight might actually be causing you to retain figure-destroying belly fat. That 's because dieting is stressful. You worry about what to eat... when to eat... how much to eat. All that worry leads to 'diet stress,' according to the experts at the Carter-Reed Company(TM), the makers of America's most popular 'Belly Fat' pill, Relacore(R)
Wed, 05 Mar 2008, 10:28:02 EST
TEMPE, Ariz., March 5 (SEND2PRESS NEWSWIRE) -- Superbowl quarterback, Tom Brady has agreed to be the face of Myo-Med, for the launch of their 2008 media campaign. BioForce, the makers of Myo-Med, recently appointed STG Media Corp. as their agency of record to assist them in creating brand awareness among athletes and arthritis sufferers nationwide.
Fri, 15 Feb 2008, 09:55:36 EST
NEW YORK, N.Y. - Feb. 15 (SEND2PRESS NEWSWIRE) -- As crazy as it sounds, recent studies conducted at Stanford and Wake Forest Schools of Medicine suggest there's a connection between stubborn stress-related belly bulge, unsightly acne flare-ups and the so-called 'Belly Fat' pill, Relacore(R)... and that link is stress. Well, now it seems that stress also increases both the frequency and the severity of acne breakouts. While this may be terrible news for millions of us who seem to be stressed-out even on the best of days, it turns out to be great news for the Carter-Reed Company.
deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients
Fri, 04 Jan 2008, 11:28:55 EST
AUSTIN, Texas - Jan. 4 (SEND2PRESS NEWSWIRE) -- deverus, Inc., the leader in background screening technology, recently announced a partnership with eScreen Inc., a company known for its innovative drug screening technology. After comparing different providers, deverus found that no one could match the selection and quality of products that eScreen had to offer. Through eScreen, deverus will now provide clients with technology that creates a web-based system that delivers faster drug test results and paperless transactions.
Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Tue, 18 Dec 2007, 10:58:09 EST
SAN MARINO, Calif. - Dec. 18 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today their appreciation of the accomplishments of their contemporaries in 2007, a truly remarkable year in terms of biomedical research, scholarship, and gonzo journalism. It was a year in which a definitive meeting entitled 'In Vivo Barriers to Gene Delivery' was held at the prestigious Cold Spring Harbor Laboratory, where Nobel laureate James Watson presides, or shall we say presided.
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G, a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Mon, 17 Dec 2007, 14:46:32 EST
SAN MARINO, Calif. - Dec. 17 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the company has received a Certificate of Product Registration for Rexin-G(R) from the Philippine Bureau of Food and Drugs (BFAD), enabling the commercialization of its lead product as a safe and effective treatment for a broad spectrum of intractable cancers. Developed as a tumor-targeted anticancer agent, that actively seeks out and destroys metastatic cancers, Rexin-G exhibits unprecedented single-agent efficacy.
Tue, 20 Nov 2007, 16:18:41 EST
LONDON, U.K. and NEW YORK, N.Y. - Nov. 20 (SEND2PRESS NEWSWIRE) -- With the ever-increasing pressure to ensure maximum return on investment, sales force effectiveness is becoming a high priority in the global pharmaceutical industry. Reports have shown that while sales forces represent the largest spend in pharma sales and marketing, return on this investment has declined sharply in recent years.
FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A.
Mon, 05 Nov 2007, 07:37:06 EST
SAN MARINO, Calif. - Nov. 5 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the company has taken a major step toward the commercialization of its lead product with the opening of a Phase II Registration Protocol using Rexin-G for osteosarcoma in the United States. Following the accelerated approval of Rexin-G for the treatment of all solid tumors by the Bureau of Food and Drugs in the Philippines.
Thu, 11 Oct 2007, 20:58:00 EST
RICHMOND, Texas - Oct. 11 (SEND2PRESS NEWSWIRE) -- OCuSOFT Inc., producer of the popular ocular-lid hygiene products, OCuSOFT(R) Lid Scrub(TM) and OCuSOFT(R) Lid Scrub(TM) PLUS, is responding to a recent advertisement released by Advanced Vision Research (AVR) that was found to be misleading.
Mon, 06 Aug 2007, 19:46:00 EST
RICHMOND, Texas - Aug. 6 (SEND2PRESS NEWSWIRE) -- CYNACON /OCuSOFT(R) (OCuSOFT, Inc.) specializes in ophthalmic research, development and supply to ophthalmologists and optometrists. They are excited to announce a new and innovative prescription-only ALODOX(R) Convenience Kit for adjunctive eyelid therapy and hygiene.
U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas - New Clintelligence(R) Alignment Module Advances Global Management
Tue, 12 Jun 2007, 18:00:00 EST
KENILWORTH, N.J. - June 12 (SEND2PRESS NEWSWIRE) -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.
News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
Mon, 04 Jun 2007, 17:38:00 EST
SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced the publication of a historic landmark in medical oncology and a definitive benchmark in the emerging field of cancer gene therapy. The first clinical report of its kind, Le Morte du Tumour - published in the June issue of the International Journal of Oncology, Vol.30, pp. 1297-1307 - documents the histologic features of tumor destruction observed in chemo-resistant cancers.
Epeius Biotechnologies Reaches Out to American Cancer Patients, Gains FDA Approval for Two New Clinical Trials Using Rexin-G(TM) for Breast Cancer and Sarcoma
Mon, 04 Jun 2007, 15:53:00 EST
SAN MARINO, Calif. - June 4 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today the expansion of ongoing clinical trials using Rexin-G(TM) in the United States to include breast cancer and all types of sarcomas that have failed standard chemotherapy. Following on the heels of their landmark clinical trials in the United States and abroad, the US FDA granted Orphan Drug Status for Rexin-G.
Drug Development Costs Exceed $802 Million: Global Pharmas Use Clintelligence to Do Something About It
Wed, 02 May 2007, 19:00:00 EST
KENILWORTH, N.J. - May 2, 2007 (SEND2PRESS NEWSWIRE) -- 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announced today that it has aligned with yet another Global Pharmaceutical Firm to implement Clintelligence - 3C Company's Business Intelligence Solution for strategic and tactical oversight of their Research and Development portfolio.
Thu, 26 Apr 2007, 20:44:00 EST
SALT LAKE CITY, Utah - Apr. 26 (SEND2PRESS NEWSWIRE) -- This provocative opening line from a television commercial for a 'mood elevating' pill has really struck a nerve. If the overwhelming response to the Libutol(TM) ad is any indication, it seems American women are more tired, distressed and unhappy than most experts (and women themselves) are willing to admit. That's the logical conclusion drawn from the phenomenal reaction women are having to Libutol, 'The Little Yellow Pill That Makes Life Better' from Blackett Pharmacal(TM).
Updated: Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G as Treatment for Diverse Metastatic Cancers
Wed, 06 Dec 2006, 20:35:00 EST
SAN MARINO, Calif. and TOKYO, Japan - Dec. 6, 2006 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G(TM) in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy.
Japanese Study Confirms Safety and Efficacy of Intravenous Rexin-G(TM) as Treatment for Diverse Metastatic Cancers
Wed, 06 Dec 2006, 13:45:00 EST
SAN MARINO, Calif. and TOKYO, Japan - Dec. 6 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies announced today the first results of an independent study conducted in Japan that further documents the safety and efficacy of intravenous Rexin-G in a broad spectrum of patients with chemo-resistant metastatic cancer. Although the study began in October, only two months ago, the initial reports are both encouraging and noteworthy. The lead investigator of the Japanese study, Dr. Takaki Imamura, will be presenting his findings and clinical recommendations at a special medical conference to be held in Tokyo, Japan, on December 16, 2006.
Wed, 11 Oct 2006, 16:18:00 EST
SAN MARINO, Calif. - Oct. 11 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation today announced that Dr. Frederick Hall, President and CEO of Epeius Biotechnologies, has accepted an invitation to speak at the upcoming Global Pharmaceutical Research & Development Summit held on Oct. 24 at 4:10 p.m. (PT) in Anaheim, Calif. Dr. Hall will present the current status of global development and the broad pharmaceutical indications for the company's innovative targeting technology platform that has enabled Epeius to develop Rexin-G(TM).
Reaction Biology Corp. Awarded NIH SBIR Grant for Kinase Radioisotope Microarray Screening Development
Tue, 20 Jun 2006, 15:15:00 EST
MALVERN, Pa. (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation (RBC) today announced that it has been awarded an SBIR grant from the National Cancer Institute to create a new kinase profiling and high throughput screening method using radioisotopes and microarrays. The $940,000 grant will be used to migrate the current well-plate radioisotope methods onto RBC's DiscoveryDot nanoliter screening platform.
Epeius Biotechnologies Corporation Receives $400,000 Grant to Support Gene Therapy Trials for Pancreatic Cancer
Mon, 19 Jun 2006, 16:07:00 EST
SAN MARINO, CA - June 19 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Company has been awarded a $400,000 grant by the Lazarex Cancer Foundation to expand and support ongoing cancer gene therapy clinical trials for advanced and metastatic pancreatic cancer.
Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies
Fri, 07 Apr 2006, 15:40:00 EST
SAN MARINO, CA - Apr. 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.
Tue, 10 Jan 2006, 11:09:00 EST
CALGARY, AB - Jan. 10 (SEND2PRESS NEWSWIRE) -- A global flu pandemic with up to a billion fatalities is coming and humanity is quite unprepared. If vaccines aren't available, what will governments do to keep their citizens alive and healthy so the world economy does not crash? Hyperimmune Egg, the Super Egg, is a food supplement that can 'help the body achieve a balanced immune system' says Dr. Verna Mackey, CEO of Baby Boomer Productions.
Mon, 12 Dec 2005, 15:06:00 EST
JAMESVILLE, VA - Dec. 12 (SEND2PRESS NEWSWIRE) -- When family and friends get together for the holidays, the kids may come home with an unexpected gift, warn the head lice experts at Dermedics Laboratories, Jamesville, VA. And this is one gift you can't just return.
Tue, 29 Nov 2005, 12:09:00 EST
FORT LAUDERDALE, FL - Nov. 29 (SEND2PRESS NEWSWIRE) -- Invision International Health Solutions, Inc., a pioneer in the field of ionic silver use in humans, recently announced the issuance of a U.S. Patent on its 'Ionic Silver Complex' technology.
Mon, 29 Aug 2005, 20:34:00 EST
JAMESVILLE, VA - August 29 (SEND2PRESS NEWSWIRE) -- A new homeopathic shampoo from Dermedics Laboratories helps stop the spread of head lice, saves kids embarrassment and reduces exposure to toxins. To a child, back to school means a new backpack, a new teacher, and new friends. For parents, it may also mean a new problem: head lice! Getting a note from the teacher warning that head lice are rampant in your child's class - or worse, not getting a note but having your child come home scratching furiously - can be the start of a parental nightmare.
Breakthrough New Ergonomic Hand Sanitizer to be Introduced to Nation's Top Hospital Infection Fighters
Thu, 07 Apr 2005, 15:42:00 EST
SANTA BARBARA, Calif. -- (SEND2PRESS NEWSWIRE) -- The nation's top hospital infection fighters will be getting a look at a new breakthrough ergonomic hand sanitizer that holds the promise of preventing 20,000 to 50,000 U.S. deaths each year. Sprixx is an alcohol hand sanitizer dispenser that you wear, use on-the-go, and is ergonomically designed to become a second-nature habit in use.
Wed, 06 Apr 2005, 12:05:00 EST
LOS ANGELES, Calif. -- (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corp. announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Rexin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer.
Novel Patented Technology Enables Low Cost, Instant Ultraviolet Disinfection for Home and Personal Care Products
Mon, 14 Feb 2005, 14:17:00 EST
BOSTON, MA /Send2Press Newswire/ -- Ultraviolet disinfection technology developed for hospital-use now available for a number of home and personal care products such as toothbrushes, pacifiers, drinking cups, knives, cutting boards, etc. reports UVSolutions, LLC (www.uvs-ultraclean.com).
NOTICE: The content of the above press releases were provided by the “news source” for each news story, who is solely responsible for its accuracy. Send2Press® is the originating wire service for these stories with newswire copies Copr. © Send2Press (a service of Neotrope). All trademarks acknowledged. Send2Press does not represent the companies found above and for questions or comments you must contact those companies directly.